Natera EBITDA

Mitä Natera tekee? Natera Inc. is an American company headquartered in San Carlos, California. It was founded in 2004 by Matthew Rabinowitz and has been listed on the NASDAQ under the ticker symbol "NTRA" since 2015. The company is a leading provider of diagnostic tests and analyses and specializes in genetic analysis and diagnostic technologies. Natera specializes in tests for various medical areas, particularly in oncology diagnostics. The company's vision is to improve the quality of life for millions of people worldwide by offering innovative diagnostic tests to detect diseases early and ensure optimal treatment. Natera offers a wide range of products tailored to the needs of consumers, physicians, and scientists. The company operates in three business areas: 1) Women's Health: Natera offers tests for women and couples to determine the risk of hereditary diseases. For example, the company offers a test that allows analysis of fetal DNA from the mother's blood, allowing detection of genetic abnormalities in the fetus before birth. Additionally, Natera offers the Panorama test, which provides tests for genetic anomalies in unborn babies that can be used to determine the risk for chromosomal abnormalities and genetic mutations. 2) Oncology: In the field of oncology, Natera offers a wide range of diagnostic tests targeting developments and trends in cancer research. The tests aim to enable accurate diagnosis and prognosis, as well as provide individualized treatment for each patient. The company offers tests that assess the current tumor growth and metastatic potential, enable determination of tumor burden in cells, and provide tests for specific mutations required for determining optimal treatment. 3) Genomic Analysis: In the field of genomic analysis, Natera offers a broad range of tests available to researchers and scientists. This includes genetic variants and biological mechanisms that cause diseases. The company is also committed to developing its tests through artificial intelligence (AI) and machine learning. The goal is to provide more accurate and faster results, improve clinical decisions, and advance research and development of new diagnostics. Conclusion: Natera is a leading company in the field of diagnostic tests and analyses in the field of genomic analysis. The company has a long history of research and development of innovative product solutions for the medical community. One important focus of the company is to improve women's health and be able to detect risks for genetic diseases early; the other focus is on oncology diagnostic tools to determine optimal treatment for cancer patients. The company is constantly striving to further develop its tests and integrate new research findings and technologies to support the medical science community. Natera on yksi Eurpooliin suosituimmista yhtiöistä.